MedTrace Logo

Expanded Access for Pembrolizumab (MK-3475)

NCT03311542 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2018-01-10

No results posted yet for this study

Summary

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab, BRAF and MEK inhibitors. The patients whose tumors are EGFR, MET or ALK positive should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with pembrolizumab.

Conditions

  • Melanoma (Skin)
  • Melanoma Recurrent
  • Glioblastoma Multiforme
  • Glioblastoma by Gene Expression Profile
  • Glioma of Brain

Interventions

BIOLOGICAL

pembrolizumab

Each participant will receive pembrolizumab every 21 days for up to 12 month or until confirmed disease progression on MRI or CT, unacceptable toxicity, confirmed.positive pregnancy test or withdrawal of consent.

Sponsors & Collaborators

  • Center Trials & Treatment

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Belarus
  • Hong Kong
  • Tajikistan
  • Uzbekistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03311542 on ClinicalTrials.gov